Thus, the therapeutic effect of CAV-SCN1A in both brain regions, despite possible divergent mechanisms, further highlights the potential of this approach and, critically, our limited understanding of DS pathophysiology. The gene discussed is SCN1A; the disease is Dravet syndrome.